Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxMinority InterestNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Gyre Therapeutics (GYRE) Accumulated Expenses: 2009-2025

Historic Accumulated Expenses for Gyre Therapeutics (GYRE) over the last 17 years, with Sep 2025 value amounting to $11.8 million.

  • Gyre Therapeutics' Accumulated Expenses rose 23.51% to $11.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $11.8 million, marking a year-over-year increase of 23.51%. This contributed to the annual value of $10.6 million for FY2024, which is 11.06% down from last year.
  • According to the latest figures from Q3 2025, Gyre Therapeutics' Accumulated Expenses is $11.8 million, which was down 20.94% from $14.9 million recorded in Q2 2025.
  • Over the past 5 years, Gyre Therapeutics' Accumulated Expenses peaked at $17.2 million during Q1 2025, and registered a low of $708,000 during Q3 2023.
  • In the last 3 years, Gyre Therapeutics' Accumulated Expenses had a median value of $10.6 million in 2024 and averaged $9.1 million.
  • Its Accumulated Expenses has fluctuated over the past 5 years, first plummeted by 63.79% in 2022, then spiked by 1,360.14% in 2024.
  • Over the past 5 years, Gyre Therapeutics' Accumulated Expenses (Quarterly) stood at $1.5 million in 2021, then skyrocketed by 531.49% to $9.3 million in 2022, then climbed by 28.83% to $11.9 million in 2023, then declined by 11.06% to $10.6 million in 2024, then increased by 23.51% to $11.8 million in 2025.
  • Its last three reported values are $11.8 million in Q3 2025, $14.9 million for Q2 2025, and $17.2 million during Q1 2025.